Anti-MEG10/ MEGF10/ EMARDD monoclonal antibody

Anti-MEG10/ MEGF10/ EMARDD antibody for FACS & in-vivo assay

Target products collectionGo to MEGF10/MEGF10 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0804-Ab-1/ GM-Tg-hg-MP0804-Ab-2Anti-Human MEGF10 monoclonal antibodyHuman
GM-Tg-rg-MP0804-Ab-1/ GM-Tg-rg-MP0804-Ab-2Anti-Rat MEGF10 monoclonal antibodyRat
GM-Tg-mg-MP0804-Ab-1/ GM-Tg-mg-MP0804-Ab-2Anti-Mouse MEGF10 monoclonal antibodyMouse
GM-Tg-cynog-MP0804-Ab-1/ GM-Tg-cynog-MP0804-Ab-2Anti-Cynomolgus/ Rhesus macaque MEGF10 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0804-Ab-1/ GM-Tg-felg-MP0804-Ab-2Anti-Feline MEGF10 monoclonal antibodyFeline
GM-Tg-cang-MP0804-Ab-1/ GM-Tg-cang-MP0804-Ab-2Anti-Canine MEGF10 monoclonal antibodyCanine
GM-Tg-bovg-MP0804-Ab-1/ GM-Tg-bovg-MP0804-Ab-2Anti-Bovine MEGF10 monoclonal antibodyBovine
GM-Tg-equg-MP0804-Ab-1/ GM-Tg-equg-MP0804-Ab-2Anti-Equine MEGF10 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0804-Ab-1/ GM-Tg-hg-MP0804-Ab-2; GM-Tg-rg-MP0804-Ab-1/ GM-Tg-rg-MP0804-Ab-2;
GM-Tg-mg-MP0804-Ab-1/ GM-Tg-mg-MP0804-Ab-2; GM-Tg-cynog-MP0804-Ab-1/ GM-Tg-cynog-MP0804-Ab-2;
GM-Tg-felg-MP0804-Ab-1/ GM-Tg-felg-MP0804-Ab-2; GM-Tg-cang-MP0804-Ab-1/ GM-Tg-cang-MP0804-Ab-2;
GM-Tg-bovg-MP0804-Ab-1/ GM-Tg-bovg-MP0804-Ab-2; GM-Tg-equg-MP0804-Ab-1/ GM-Tg-equg-MP0804-Ab-2
Products NameAnti-MEGF10 monoclonal antibody
Formatmab
Target NameMEGF10
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-MEGF10 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species MEG10/ MEGF10/ EMARDD VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0804
    Target NameMEGF10
    Gene ID84466,70417,291445,703899,474665,101087898,539136,100063589
    Gene Symbol and Synonyms3000002B06Rik,CMYP10A,CMYP10B,EMARDD,Gm331,MEGF10,SR-F3
    Uniprot AccessionQ96KG7
    Uniprot Entry NameMEG10_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000145794
    Target ClassificationN/A

    The target: MEGF10, gene name: MEGF10, also named as EMARDD. This gene encodes a member of the multiple epidermal growth factor-like domains protein family. The encoded protein plays a role in cell adhesion, motility and proliferation, and is a critical mediator of apoptotic cell phagocytosis as well as amyloid-beta peptide uptake in the brain. Expression of this gene may be associated with schizophrenia, and mutations in this gene are a cause of early-onset myopathy, areflexia, respiratory distress, and dysphagia (EMARDD) as well as congenital myopathy with minicores. Alternatively spliced transcript variants have been observed for this gene. [provided by RefSeq, Apr 2012].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.